Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.48 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3643499 | 0.94 | P4HTM (0.50) | P4HTMRAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL4247747 | 0.91 | P4HTM (0.53) | P4HTMRAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL3646879 | 0.89 | EPHX1 (0.53) | P4HTMRAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL3642334 | 0.86 | P4HTM (0.58) | P4HTMRAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL4253528 | 0.86 | P4HTM (0.51) | P4HTMRAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL8083748 | 0.86 | EGFR (0.43) | P4HTMRAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL4255579 | 0.85 | NPC1 (0.55) | P4HTMRAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL4247552 | 0.83 | P4HTM (0.55) | P4HTMRAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL4248558 | 0.82 | P4HTM (0.62) | P4HTMRAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3639325 | 0.81 | P4HTM (0.64) | P4HTMRAB9ANPC1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101765425-A | Use of benzamide derivatives for the treatment of CNS disorders | HOFFMANN LA ROCHE | 2010-06-30 | — | — | CN | claimed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | claimed |
| US-20240307361-A1 | METHOD FOR DIAGNOSING AND TREATING IRRITABLE BOWEL SYNDROME | Centre for Chinese Herbal Medicine Drug Development Limited (CN) | 2024-09-19 | — | — | US | disclosed |
| US-20240295566-A1 | METHOD FOR DIAGNOSING AND TREATING METABOLIC DISORDERS | Centre for Chinese Herbal Medicine Drug Development Limited (CN) | 2024-09-05 | — | — | US | disclosed |
| CN-101765425-A | Use of benzamide derivatives for the treatment of CNS disorders | HOFFMANN LA ROCHE | 2010-06-30 | — | — | CN | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240307361-A1 | METHOD FOR DIAGNOSING AND TREATING IRRITABLE BOWEL SYNDROME | HRH4, VIPR1, TAAR1 | P4HTM 2230/4885RAB9A 861/4885NPC1 3272/4885 |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | GABBR1, GABBR2, CHRM2 | P4HTM 2004/4885RAB9A 733/4885NPC1 869/4885 |
| US-20240295566-A1 | METHOD FOR DIAGNOSING AND TREATING METABOLIC DISORDERS | TPH1, GPR119, TAAR1 | P4HTM 1591/4885RAB9A 1253/4885NPC1 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.